Eqvista joins a conversation with George Crane, Co-Founder and CEO of Bindbridge, to discuss the journey of a startup bringing fresh thinking to agriculture through AI-driven molecular discovery. In this conversation, George shares how Bindbridge was founded at the intersection of science, technology, and a pressing industry need: the search for safer, more effective, and more sustainable crop protection solutions.
George also discusses the opportunities and challenges of building a company in a highly regulated, highly complex sector, and on why the future of agriculture may be shaped by novel approaches such as targeted protein degradation and generative AI.
George, what was the moment that led you to co-found Bindbridge? Was there a specific problem you encountered in industry that no existing solution was addressing adequately?
During my time at Yara Growth Ventures, I spent a lot of time looking at the next generation of crop protection technologies. One trend became very clear: many of the most promising agchem startups were adapting derisked technologies from pharma and applying them to agriculture.
The challenge was that many of those technologies were never truly designed for field conditions. They were often too expensive, too fragile, or too complex to scale economically in agriculture. At the same time, the crop protection industry was entering a period of enormous pressure. Herbicide resistance continues to spread globally, regulatory scrutiny is increasing, and the pipeline of genuinely novel modes of action remains historically thin. Major incumbents are restructuring R&D operations and focusing heavily on productivity and differentiated innovation.
We saw an opportunity at the intersection of two major technological shifts: AI-driven molecular discovery and targeted protein degradation (TPD) via molecular glues. In pharma, TPD has already become one of the most exciting new therapeutic modalities, with the first PROTAC drugs reaching regulatory approval and major pharma companies signing multi-billion-dollar AI discovery partnerships. Our belief was simple: if this modality is transformative in medicine, it is inevitable that it will eventually reshape agriculture as well. Bindbridge was founded to accelerate that transition.
Could you walk us through how Bindbridge works? What does a customer’s journey look like from onboarding to realizing value?
Bindbridge is a Generative AI platform for the discovery and design of molecular glues for agriculture. We use AI-based approaches to model plant proteins and design or screen small molecules predicted to induce affinity between a Protein of Interest (POI) and a naturally occurring protein degrader, typically an E3 ligase. In simple terms, we are programming selective protein degradation inside plants.
Once we identify promising chemistries computationally, we validate them experimentally through biochemical assays, plant cell studies, and ultimately glasshouse and field trials.
Our initial focus is herbicide-resistant weeds, which are responsible for an estimated $70B+ in annual crop losses globally. However, the platform itself is modality-agnostic and can be extended into fungicides, insecticides, and even crop enhancement applications such as biostimulants.
We typically engage customers in two ways:
1. Licensing lead compounds – where Bindbridge has already developed validated molecules demonstrating efficacy in laboratory and glasshouse environments.
2. Joint Development Agreements (JDAs) – where we collaborate directly with crop protection companies on strategically selected targets.
Some partners come to us with a predefined biological target, while in other cases we proactively introduce internally discovered degrader systems and POIs that we believe represent commercially compelling opportunities.
The value proposition for customers is ultimately about speed, novelty, and efficiency. Traditional phenotypic screening campaigns can take years and require screening hundreds of thousands of compounds. AI-guided targeted degradation offers a path toward entirely new modes of action with significantly faster iteration cycles and lower discovery costs.
Many founders discover their initial assumption about the problem was slightly off-target once they got into the market. Did that happen with Bindbridge?
One thing I learned early in venture is that founders should be led by industry pain points, not by technology searching for a problem.
Because Bindbridge is fundamentally a platform technology company, there are almost infinite scientific directions we could pursue. The real challenge is maintaining discipline and ensuring that what we build aligns with the commercial realities of agriculture.
What became clearer after entering the market was just how important customer alignment is at every stage. In agriculture, technical elegance alone is not enough. Products must fit into existing regulatory frameworks, distribution systems, grower economics, and resistance-management strategies. That has reinforced our belief that close collaboration with the industry is essential. We don’t want to build scientifically interesting technology that ultimately sits on a shelf. We want to solve commercially urgent problems.
When you were validating the market need early on, what was the most surprising piece of feedback you received from potential customers or partners?
I already knew the crop protection industry moved slowly, but I was still surprised by just how much technical and biological derisking large agchem companies now expect before engaging seriously.
There is understandably a strong preference for technologies that are already approaching commercial readiness. Part of that reflects broader industry economics. Margins across crop protection have been under pressure for several years due to generic competition, pricing compression, and regulatory complexity. We are now seeing major industry restructurings and cost-cutting initiatives across the sector.
As a result, large players increasingly expect startups to absorb a greater portion of the early-stage scientific risk.
While understandable from their perspective, it can slow the adoption curve for breakthrough technologies. One of our goals at Bindbridge is therefore to aggressively compress the derisking timeline through AI-enabled discovery and highly targeted experimental validation.
Many B2B startups struggle with long enterprise sales cycles. How have you managed that challenge while maintaining runway and momentum?
Long enterprise sales cycles are simply part of the reality in agriculture, particularly in crop protection. These companies operate in highly regulated global markets, and product development timelines are measured in years rather than quarters.
For us, the key has been aligning capital strategy with industry reality. We are fortunate to have investors who understand the timelines associated with agricultural innovation and appreciate the strategic importance of building durable technology platforms.
Operationally, that means maintaining disciplined burn rates, planning around worst-case sales assumptions, and ensuring that every technical milestone meaningfully increases enterprise value.
It is also important to recognize that agriculture differs from sectors like software or consumer tech. Exit valuations are often more modest relative to the amount of technical work required, which fundamentally changes how founders need to think about capital efficiency.
What was the hardest technical or operational challenge your team had to overcome to get the product to where it is today?
Bindbridge sits at the intersection of several highly specialized disciplines: biology, chemistry, AI, structural modeling, and commercial agriculture.
One of the hardest challenges has been creating a common operating framework across those domains.
A commercially valuable crop protection product starts with a real-world agricultural problem, but translating that into molecular biology, computational modelling, chemistry design, and experimental validation requires very different scientific languages and ways of thinking.
Fortunately, we have built a deeply interdisciplinary team with experience across both advanced science and industrial product development. Over time, we developed an internal process that allows us to align commercial requirements with scientific feasibility before committing substantial resources.
That alignment is critical because experimentation in this field can become extremely expensive if teams are not tightly coordinated.
Congratulations on Bindbridge’s recent $3.8M seed funding. What did your investors see in Bindbridge that you believe others who passed on the round missed?
We were fortunate to partner with two exceptional investors in Speedinvest and Nucleus Capital.
Both firms understood not only the scale of the agricultural problem space, but also the broader significance of targeted protein degradation and AI-enabled molecular discovery.
Bindbridge exists at a fairly unique intersection of science, cutting-edge computational methods and AI, and agricultural industries. For investors without domain expertise in all three areas, the technical uncertainty can understandably feel intimidating.
Our investors recognized something that is becoming increasingly clear across both pharma and agriculture: AI is not simply improving discovery workflows incrementally – it is fundamentally changing what types of molecules and biological interactions are discoverable.
At the same time, the crop protection industry is urgently searching for new modes of action as resistance spreads globally. We believe molecular glues represent one of the most promising new modalities to emerge in decades.
How did you approach the valuation conversation? Did you anchor the number, or did you let the market tell you what Bindbridge was worth?
Having self-funded the company through its earliest stages, we naturally had a valuation range in mind. That said, the financing environment today is very different from the 2021 market. We approached the process pragmatically and ultimately allowed the market to determine pricing.
Interestingly, once we reached the later stages of the round, the term sheets converged relatively closely in valuation.
That actually made investor quality, strategic alignment, and long-term conviction significantly more important than squeezing out the absolute highest number.
At this stage, having investors who genuinely understand the pace and complexity of agricultural innovation is worth far more than optimizing for a slightly higher headline valuation.
What macro trends — whether in technology, regulation, or economic shifts — do you believe will most significantly impact your industry over the next 3–5 years?
The crop protection industry is under pressure from multiple directions simultaneously.
Regulatory requirements continue to tighten globally, herbicide and fungicide resistance are increasing, and generic manufacturers – particularly from Asia – are exerting significant pricing pressure on incumbent chemistry portfolios.
At the same time, the pipeline of novel crop protection products has become increasingly sparse, making it difficult for large incumbents to sustain historical R&D economics.
We are already seeing the consequences play out publicly. Major crop protection companies are restructuring operations, consolidating R&D, and prioritizing technologies capable of delivering differentiated value rather than incremental chemistry.
Against that backdrop, I believe two trends will fundamentally reshape the industry over the next five years:
1. AI-native discovery workflows
2. Targeted protein degradation as a new agricultural modality
The broader pharmaceutical industry has already validated both trends. We are seeing major AI-drug discovery partnerships worth billions of dollars, alongside increasing commercial validation of targeted protein degradation technologies.
Agriculture historically adopts breakthrough technologies after pharma, but eventually at enormous scale.
Bindbridge was founded on the belief that these technologies will inevitably transition into agriculture – and that they can unlock entirely new classes of crop protection and crop enhancement products at dramatically lower discovery cost and faster development timelines.
For someone early in their entrepreneurial journey looking at the same space you’re in, what’s the one piece of advice you’d give them before they take the leap?
Agriculture is one of the most nuanced industries in the world. While at Yara Growth Ventures, I saw many founders approach the sector with the assumption that agriculture was simply “broken” and waiting for disruption. In reality, agriculture is highly fragmented, deeply regulated, operationally complex, and dominated by entrenched global incumbents.
There are very real constraints around farmer behavior, channel distribution, regulation, field performance, and economics. The founders who succeed are usually the ones who spend significant time understanding the industry before trying to reinvent it.
My advice would therefore be simple: start with the grower, the regulator, and the commercial reality – not with the technology.
Technology matters enormously, but in agriculture, success usually comes from respecting the complexity of the system rather than underestimating it.
And honestly, the classic “Ag is broken” slide from an MBA graduate with no industry experience still terrifies me today – probably even more now than it did a few years ago.
